Mumbai, February 14:
India’s leading Contract Development and Manufacturing Organization (CDMO), Akums Drugs & Pharmaceuticals Limited, has delivered an impressive financial performance in the third quarter of FY26, reporting strong growth across key business segments.
The company posted a sharp rise in both revenue and profitability for the quarter ended December 31, 2025, reflecting robust demand, improved volumes, and better operational efficiency.
Revenue Up 14.8% to ₹1,160 Crore
According to the company’s quarterly results, Akums reported a 14.8% year-on-year increase in revenue, reaching ₹1,160 crore in Q3 FY26. In the corresponding quarter of the previous year, the company had recorded revenue of ₹1,010 crore.
The growth was driven mainly by higher production volumes and strong performance across multiple business divisions.
Profit After Tax Surges 29.5%
Akums also reported a major jump in profitability. The company’s adjusted Profit After Tax (PAT) increased by 29.5%, rising to ₹86 crore during the quarter.
This strong profit growth highlights the company’s improving margins and rising demand for its contract manufacturing services.
Adjusted EBITDA Rises 21%
The company’s operational performance also improved significantly. Akums recorded a 21% increase in adjusted EBITDA, which rose to ₹147 crore in Q3 FY26.
Meanwhile, overall EBITDA grew marginally by 1%, reaching ₹370 crore for the quarter.
CDMO Segment Remains Key Growth Driver
Akums’ core business — contract manufacturing under the CDMO segment — continued to lead growth. The company reported that revenue in this segment rose by over 16% during the quarter, largely driven by double-digit volume growth.
In addition, the international branded formulations segment witnessed more than a two-fold increase compared to the previous quarter, supported by improving demand in key overseas markets.
Major Regulatory Milestones Achieved
During the quarter, Akums made notable progress in strengthening its global manufacturing credentials.
The company successfully secured European Union Good Manufacturing Practice (EU GMP) certification for two of its manufacturing facilities. This includes:
- renewal of EU GMP approval for its oral solids plant, and
- fresh EU GMP approval for its oral liquids plant.
Further strengthening its regulatory standing, Akums also received approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the manufacturing of Rivaroxaban tablets, marking the company’s first such clearance from the UK regulator for this product.
Share Price Declines Despite Strong Results
Despite the strong quarterly performance, Akums’ share price declined on Friday amid a broader market sell-off. The BSE Sensex fell by 1,048.16 points, creating heavy pressure across sectors.
As a result, Akums Drugs & Pharmaceuticals shares closed 2.95% lower, falling by ₹13.70 to end at ₹450.65 on the BSE on February 13, 2026.
Outlook
With strong revenue momentum, improving profitability, and expanding international regulatory approvals, Akums Drugs appears well-positioned for further growth in the coming quarters. Analysts believe the company’s rising global footprint and strengthening CDMO demand could continue to support its long-term expansion strategy.
Discover more from SD NEWS agency
Subscribe to get the latest posts sent to your email.